Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma

NCT02043847 is registered in ClinicalTrials.gov with University of Illinois at Chicago as lead sponsor.

NCT NCT02043847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02043847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
University of Illinois at Chicago
Phase
Phase 1
Overall status
Completed
Start date
January 14, 2014
Completion date
September 14, 2016
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, refractory to standard treatment, multiple myeloma, relapsed